Sign in Subscribe
Cancer research

Breakthrough in Non-Small Cell Lung Cancer Treatment: Research Suggests Combination Therapy with Traditional Chinese Medicine

Strategic Insights

— 2 min read

Research conducted at the Gansu University of Chinese Medicine in People's Republic of China has led to a potential breakthrough in the treatment of non-small cell lung cancer (NSCLC). The study, published in the journal Frontiers in Oncology, investigates the benefits and risks of combining Fuzheng Yiliu Decoction, a traditional Chinese medicine, with conventional chemotherapy. The findings suggest that the combination therapy not only improves therapeutic efficacy but also reduces chemotherapy's adverse side effects, offering a promising treatment strategy for NSCLC.

Key Takeaways:

  • The study used multi-criteria decision analysis (MCDA) to evaluate the benefits and risks of combining Fuzheng Yiliu Decoction with chemotherapy in treating NSCLC.
  • A comprehensive literature search identified 6 randomized controlled trials (RCTs) comparing chemotherapy alone with chemotherapy combined with Fuzheng Yiliu Decoction.
  • The MCDA model showed that the combination therapy had significantly higher benefit values (72) compared to chemotherapy alone (29).
  • The risk value for combination therapy (56) was slightly higher than that of chemotherapy alone (24), but the overall benefit-risk value for combination therapy (68) was notably greater than chemotherapy alone (27).
  • Monte Carlo simulations revealed a difference in total efficacy-risk values between the two treatments of 41 (95% CI: -16.59, 38.73).
  • The probability that the combination therapy's benefit-risk value exceeds that of chemotherapy alone was 81.83%.
  • The study suggests that combining Fuzheng Yiliu Decoction with chemotherapy improves therapeutic efficacy and reduces chemotherapy's adverse side effects, offering a promising treatment strategy for NSCLC.

Statistics:

  • 72: Benefit value for combination therapy with Fuzheng Yiliu Decoction and chemotherapy.
  • 29: Benefit value for chemotherapy alone.
  • 56: Risk value for combination therapy with Fuzheng Yiliu Decoction and chemotherapy.
  • 24: Risk value for chemotherapy alone.
  • 68: Benefit-risk value for combination therapy with Fuzheng Yiliu Decoction and chemotherapy.
  • 27: Benefit-risk value for chemotherapy alone.
  • 41: Difference in total efficacy-risk values between combination therapy and chemotherapy alone (Monte Carlo simulations).
  • 95%: Confidence interval for the difference in total efficacy-risk values between combination therapy and chemotherapy alone.
  • 81.83%: Probability that the combination therapy's benefit-risk value exceeds that of chemotherapy alone.

Sources:

  • NewsRx. New Findings on Non-Small Cell Lung Cancer from Gansu University of Chinese Medicine Summarized (Benefit-risk evaluation of Fuzheng Yiliu Decoction combined with chemotherapy for treating non-small cell lung cancer using multicriteria decision ...). Cancer Weekly. October 21, 2025; p 273.
  • Benefit-risk evaluation of Fuzheng Yiliu Decoction combined with chemotherapy for treating non-small cell lung cancer using multicriteria decision analysis. Frontiers in Oncology, 2025;15:1627904.

Read more